My PCR
Create Account
Logo PCR

22 May 2025

TAVI

FAITAVI - Major Late-Breaking Trial from EuroPCR 2025

PCR Perspectives

Summary

Presented at EuroPCR 2025, the FAITAVI trial brings new insights into the management of coronary artery disease in patients undergoing TAVI.

In this PCR Perspectives video, Stephan Windecker and Flavio Ribichini explore how the trial—the first of its kind—compared angiography-guided versus FFR-guided strategies for intermediate coronary lesions. The study confirmed the feasibility of FFR in this setting and provided reassuring data: revascularisation may not be necessary when lesions are not clearly severe.

What are the implications for pre-TAVI decision-making? Watch now to find out.

This interview was filmed at EuroPCR 2025: see more videos here.

Also available in podcast format:

This podcast is also available on Spotify and Apple Podcasts

Related Content
How to approach the challenges of large annuli in TAVI Step-by-step TAVI procedure in Europe and India - A review from PCR and India Valves Share your work at PCR-CIT China Chengdu Valves 2025
Recommended for you
What’s new in the 2025 guidance on valvular heart disease - ESC Congress 2025 PCR Rio Valves 2025: Discover what’s in store for this new initiative What's the best way to reduce the cost of your #AictPCR badge?